Precision Oncology Trends
The latest news on precision oncology research trends.
The companies said their partnership will allow pharmaceutical partners to measure both ctDNA and CTC biomarkers from a single blood draw when conducting drug trials.
Inivata's Radar assay will be used to monitor circulating tumor DNA from multiple tumor types in trial participants following treatment with Maverick's MVC-101 candidate.
The Phase I/II GOBLET trial will assess pelareorep plus Tecentriq in pancreatic, colorectal, and anal cancer patients and explore biomarkers of response.
The company also acquired DNA methylation analysis firm Base Genomics for $410 million and said it plans to raise $869 million in a direct stock offering.
FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer.
The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors.
Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy.
The agency issued a new draft decision memo, outlining various criteria it intends to apply when determining coverage for current and future blood-based CRC screening tests.
Researchers are continuing to collect data on economic, racial, and other factors that could be addressed to make precision medicine access more equitable.
Using RNA and DNA sequencing to predict tumor site and detect gene alterations may allow patients with CUP to receive appropriate targeted treatment.